Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Crescent Biopharma, Inc. (NASDAQ: CBIO)
CBIO Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
164%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
64.30%
CBIO Stock Analysis
CBIO
PE Ratio:
CBIO
PEG Ratio:
Not Available
CBIO
Forward EPS Growth (12 month):
0.00%
CBIO
PS Ratio:
45.7
CBIO
PSG Ratio:
0.2
CBIO
Forward Revenue Growth (12 month):
205.50%
CBIO Articles
No data was found